Phase II Study of Venetoclax as Preemptive Therapy in IGHV Unmutated High-Risk Stage A Chronic Lymphocytic Leukemia Patients

The primary objective of this study is to evaluate the efficacy of **Venetoclax** as a preemptive therapy in patients with high-risk stage A Chronic Lymphocytic Leukemia (CLL) who have unmutated IGHV. This is clinically relevant as it aims to address the need for early intervention in a subset of CLL patients who are at a higher risk of disease progression, potentially improving their prognosis and delaying the need for more aggressive treatments.

The clinical trial involves participants diagnosed with **IGHV unmutated patients with high-risk stage A chronic lymphocytic leukemia (CLL)**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population, as well as any specific lifestyle considerations such as diet or physical activity, have not been disclosed. Key inclusion or exclusion criteria are not specified in the available data.

The clinical trial is designed to evaluate the efficacy of preemptive therapy with **Venetoclax** in patients with high-risk stage A **Chronic Lymphoid Leukemia (CLL)**, specifically those with IGHV unmutated features. This is a phase II trial conducted by the FILO group. The trial follows a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated recruitment start date was May 28, 2019, with an anticipated end date of April 24, 2030, indicating a comprehensive study period to gather sufficient data.

Participants will undergo a series of study visits, beginning with an inclusion visit, also known as the screening visit, to determine eligibility based on specific criteria. Following successful inclusion, participants will attend regular follow-up visits to monitor their response to the treatment and any potential side effects. These visits are crucial for assessing the primary and secondary endpoints of the trial. The end-of-study visit will conclude the participant's involvement, where final assessments will be conducted to evaluate the overall outcomes of the therapy.

The expected length of participant involvement will vary depending on individual response and progression, but it is structured to cover the entire duration of the trial. Conditions that may lead to early termination from the study include significant adverse reactions to the treatment, withdrawal of consent, or any other medical reasons deemed necessary by the study investigators. The trial is conducted under strict ethical guidelines to ensure participant safety and the integrity of the data collected.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its **pharmaceutical form**, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is categorized as a Phase 4 study, with an estimated recruitment start date of May 28, 2019, and an estimated end date of April 24, 2030. The trial's efficacy will be assessed through parameters that are not explicitly detailed in the provided data. As such, specific endpoints, methods, and schedules for measuring, collecting, and analyzing efficacy parameters are not available. The trial's focus on efficacy assessment will align with standard practices for Phase 4 studies, which typically involve post-marketing surveillance to evaluate the long-term effectiveness and safety of a treatment. The trial will adhere to rigorous scientific and ethical standards to ensure the reliability and validity of the efficacy data collected throughout the study period.